UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or (Address of principal executive offices) (Zip Code) (347) 720-2907 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-42590 Titan Acquisition Corp (Exac ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or (State or other jurisdiction of incorporation or organization) 131 Concord Street (Address of principal executive offices) (Zip C ...

Financial Performance - For the three and nine months ended September 30, 2025, the company's RPM was $25.18 and $24.16, respectively, reflecting increases of 2% and 9% compared to the same periods in 2024[155]. - The company reported net income from continuing operations of $6,865 and $23,274 for the three and nine months ended September 30, 2025, respectively[158]. - For the three months ended September 30, 2025, total revenue decreased by $3,795, or 11.3%, to $29,760 from $33,555 in the same period of 2024[179]. - For the nine months ended September 30, 2025, total revenue increased by $16,908, or 18.9%, to $106,587 compared to $89,679 in the same period of 2024[199]. - The company reported a net income of $119,524 for the nine months ended September 30, 2025, compared to a net loss of $107,589 in 2024, representing a change of $227,113[198]. Cash Flow and Working Capital - As of September 30, 2025, the company had cash and cash equivalents of $12,523 and working capital of $26,837, a significant improvement from a working capital deficit of $82,022 as of December 31, 2024[168]. - Net cash provided by operating activities for the nine months ended September 30, 2025, was $26,131, compared to a net cash used of $7,507 in the same period of 2024[169]. - As of September 30, 2025, the company had $50,000 available for additional use under its working capital loan with Simplify[163]. Expenses and Cost Management - Operating expenses decreased by $3,507, or 39.2%, to $8,939, driven by reductions in headcount and consulting expenses[175]. - General and administrative expenses decreased by $2,810 to $3,213, primarily due to lower professional fees and improved collection efforts[184]. - Operating expenses decreased by $16,357, or 41.8%, to $22,762, primarily due to reductions in sales and marketing expenses and general and administrative expenses[199]. - General and administrative expenses decreased by $10,094, or 40.7%, to $14,696, driven by reductions in payroll and professional services[207]. - Total other expenses decreased by $3,255, or 26.5%, from $12,289 in 2024 to $9,034 in 2025[219]. Revenue Breakdown - Digital advertising revenue fell by $5,122, a decrease of 22.2%, primarily due to algorithmic updates affecting search rankings and traffic levels[178]. - Segment revenue for Sports & Leisure decreased by $4,944, while Finance and Lifestyle segments saw increases of $2,218 and $2,376, respectively[186][188]. - Segment revenue for Finance increased by $11,454, primarily due to a $7,017 increase in digital advertising revenue and a $4,722 increase in performance marketing revenue[210]. - Digital revenue increased by $17,512, or 19.9%, to $105,642, driven by a $4,921 increase in digital advertising revenue and a $9,306 increase in performance marketing revenue[202]. Profitability and Income - Income from continuing operations improved by $2,087 to $6,865, compared to $4,778 in the prior period[175]. - Income from continuing operations improved by $38,154 to $23,274, compared to a loss of $14,880 in the prior period, driven by increased revenue and decreased operating expenses[198]. - The company recorded a loss from discontinued operations of $(92,709) for the nine months ended September 30, 2024, which improved to income of $96,250 for the same period in 2025[167]. - The company reported a loss from discontinued operations of $96,250 for the nine months ended September 30, 2025, compared to a gain of $92,709 in 2024[224]. Other Financial Metrics - Adjusted EBITDA for the nine months ended September 30, 2025, was $41,301, compared to $13,978 in 2024, reflecting significant operational improvement[224]. - Interest expense decreased by $302 to $2,857, reflecting lower amortization of debt issuance costs and reduced interest charges[195]. - Interest expense decreased by $2,941, or 25.0%, from $11,747 in 2024 to $8,806 in 2025 due to lower debt balance after repayment of the Simplify Loan[220]. - Provision for income taxes increased by $845, from $116 in 2024 to $961 in 2025, primarily due to improved operating results[222]. - The company recorded a tax benefit of $304 for the period, compared to a tax provision of $40 in the prior year, due to tax law changes[197]. Shareholder Actions - A share repurchase program was announced on July 31, 2025, allowing the company to repurchase up to 3 million shares of common stock through July 31, 2026[173].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) For the transition period from ___________ to ____________ Commission File Number: 001-41701 NEWTON GOLF COMPANY, INC. (Exact name of registrant as specified in its charter) | Delaware | 82-4938288 | | --- | --- | | (State | (I.R.S. Employer | | of incorporation) | Identification No.) | | 551 Calle San Pablo, Camarillo, California | 93012 | | (Address of principal executive offices) | (Zip Code) | ☒ QUARTERLY REPORT ...

Financial Performance - The net loss for the nine months ended September 30, 2025, was $6,503,698, compared to a net loss of $4,025,361 for the same period in 2024, indicating an increase in losses of about 61.6%[11] - For the nine months ended September 30, 2025, eXoZymes reported a net loss of $6,503,698, compared to a net loss of $4,025,361 for the same period in 2024, reflecting an increase in losses of approximately 62%[80] - The company has substantial doubt about its ability to continue as a going concern due to anticipated funding shortfalls and its pre-revenue status[22] - The company reported no operating income for the three and nine months ended September 30, 2025, maintaining a consistent trend from the previous year[11] - The company incurred net cash used in operating activities of $(4,528,240) for the nine months ended September 30, 2025, compared to $(2,798,123) in 2024, an increase of approximately 62%[16] Assets and Equity - Total assets decreased from $13,034,404 on December 31, 2024, to $7,719,049 on September 30, 2025, representing a decline of approximately 40.5%[9] - Total stockholders' equity fell from $10,420,775 on December 31, 2024, to $5,374,422 on September 30, 2025, a decrease of approximately 48.5%[9] - Cash and cash equivalents decreased from $9,719,310 at the beginning of the period to $5,098,687 at the end of the period, a reduction of about 47%[16] - The fair value of cash and cash equivalents as of September 30, 2025, is $5,098,687, with no Level 2 or Level 3 measurements reported[42] Research and Development - Research and development costs for the nine months ended September 30, 2025, were $2,594,765, up from $1,238,463 in 2024, reflecting a significant increase of approximately 109%[11] - For the nine months ended September 30, 2025, research and development costs prior to grant offsets amounted to $3,748,110, compared to $3,046,169 for the same period in 2024, reflecting an increase of approximately 22.9%[51] - Research and development costs, net of grants, were $2,594,765 for the nine months ended September 30, 2025, compared to $1,238,463 in 2024, reflecting a significant increase of approximately 110%[1] Grants and Funding - The Department of Energy contributed 89% and the NIH contributed 11% of all grant reimbursements for the nine months ended September 30, 2025[31] - Grant reimbursements for the nine months ended September 30, 2025, totaled $1,120,907, down from $1,756,852 in 2024, indicating a decrease of about 36.3%[50] - The balance of grants receivable at the end of the nine months ended September 30, 2025, was $302,643, a decrease from $553,963 at the end of the same period in 2024, representing a decline of approximately 45.2%[48] - eXoZymes received a $3 million share of a $9.2 million grant from the U.S. National Science Foundation aimed at enhancing cell-free systems, awarded on July 1, 2025[49] Stock and Compensation - The weighted average number of common shares outstanding increased from 6,251,158 in 2024 to 8,377,513 in 2025, reflecting a growth of about 34%[11] - eXoZymes' stock-based compensation for the nine months ended September 30, 2025, was $1,066,461, compared to $808,362 for the same period in 2024[71] - The total number of stock options outstanding was 1,982,830 shares as of September 30, 2025, with a weighted average exercise price of $5.51[72] - The company has unrecognized stock-based compensation of $3,073,349 as of September 30, 2025[71] - The company issued 19,440 shares of common stock to key executives on May 12, 2025, valued at $243,778, in lieu of cash bonuses[61] Operating Costs - Total operating costs for the nine months ended September 30, 2025, were $7,020,981, up from $3,948,789 in 2024, indicating an increase of approximately 78%[1] - General and administrative costs for the nine months ended September 30, 2025, totaled $4,426,216, compared to $2,710,326 in 2024, marking an increase of approximately 63.3%[11] - The company recognized operating lease expenses of $280,898 for both the nine months ended September 30, 2025, and 2024, indicating no change year-over-year[103] Lease and Liabilities - The total lease liabilities as of September 30, 2025, amounted to $1,200,888 for operating leases and $119,236 for finance leases[104] - The company entered into a lease for new office space with an initial base rent of $13,277 per month, which will increase annually, and the lease term is set for 60 months[94] - eXoZymes has recorded right-of-use assets of $1,124,925 and operating lease liabilities of $1,200,888 as of September 30, 2025, with a weighted average remaining lease term of 3.83 years[102] Miscellaneous - The company established a wholly owned subsidiary, NCTx LLC, on May 5, 2025, focused on developing N-trans-caffeoyltyramine, a rare plant-derived compound[21] - The company is classified as an "emerging growth company," allowing it to take advantage of certain exemptions from reporting requirements[29] - The company has not generated revenue to date and is in a pre-revenue status, raising concerns about its ability to continue as a going concern without additional funding[22] - The company did not experience any credit risk losses during the three and nine months ended September 30, 2025, and 2024[38]

Revenue Performance - Total revenue for the three months ended September 30, 2025, was approximately $1.40 million, a decrease of approximately 43% compared to $2.44 million for the same period in 2024[106] - Software Services revenue was approximately $1.25 million, down approximately 44% from $2.23 million in the prior year, attributed to timing of Department of War contracts and U.S. Government budget delays[109] - Three customers accounted for approximately 79% of total gross revenues during the three months ended September 30, 2025[113] Profitability and Expenses - Gross profit margin decreased to approximately 72% for the three months ended September 30, 2025, compared to approximately 79% for the same period in 2024, primarily due to changes in the cost structure of Department of War projects[114] - Total operating expenses for the three months ended September 30, 2025, were approximately $2.34 million, a decrease of approximately 21% from $2.96 million in the prior year, reflecting the divestiture of the QReal business[115] - Research and development expenses for the three months ended September 30, 2025, were approximately $0.97 million, a decrease of approximately 13% from $1.12 million in the prior year[117] - Sales and marketing expenses decreased by approximately 57% to $0.32 million for the three months ended September 30, 2025, compared to $0.74 million in the prior year[119] - Adjusted EBITDA loss was $0.92 million for the three months ended September 30, 2025, compared to a loss of approximately $0.46 million for the same period in 2024, reflecting a decrease in revenue and gross margin[128] Net Loss and Cash Flow - Net loss for the three months ended September 30, 2025, was approximately $1.03 million, compared to a net loss of approximately $1.02 million for the same period in 2024, reflecting reduced revenue and gross margin offset by lower operating expenses[123] - Net cash used in operating activities increased to approximately $1.29 million for the three months ended September 30, 2025, from approximately $0.42 million in the same period of 2024, representing a 207% increase[130] - The net decrease in cash and cash equivalents was $1.27 million for the three months ended September 30, 2025, compared to a decrease of $0.43 million in the same period of 2024, indicating a 195% increase in cash outflow[129] Cash Position and Financing - Cash and cash equivalents at the end of the period were $5.56 million, up 294% from $1.41 million at the end of the same period in 2024[129] - The company had no outstanding debt obligations as of September 30, 2025[133] - Net cash provided by financing activities was approximately $0.03 million for the three months ended September 30, 2025, compared to zero for the prior year period[132] Strategic Initiatives - The company entered into a $2+ million SpatialCore contract to be delivered over a 12-month period starting August 13, 2025[104] - The company is exploring a potential spin-off of its BLI subsidiary to unlock shareholder value and provide growth resources, though the process is in early stages and uncertain[105] Other Financial Metrics - As of September 30, 2025, the company had $0.66 million in accounts receivable[133] - The contingent consideration for acquisition liabilities included a $1.50 million cash component, which was paid in October 2025[134] - The company experienced a flat year-over-year net cash used in investing activities, primarily related to equipment purchases[131]

Financial Performance - Consolidated net sales for fiscal year 2025 decreased by $15.6 million, or 0.4%, to $3,701.4 million, impacted by foreign currency exchange rates by $11.4 million, or 0.3%[204] - Consolidated comparable sales increased by 0.3% compared to the prior fiscal year[204] - Consolidated gross profit increased by $20.4 million, or 1.1%, to $1,910.7 million, with gross margin improving by 70 basis points to 51.6%[204] - Consolidated net earnings rose by $42.5 million, or 27.7%, to $195.9 million, with diluted earnings per share increasing to $1.89 from $1.43[204] - Net sales for fiscal year 2025 were $2,991.24 million, with a gross profit of $1,568.10 million and net earnings of $180.56 million[231] Cash Flow and Debt Management - Cash provided by operations was $274.8 million for fiscal year 2025, compared to $246.5 million for the prior fiscal year[204] - Net cash provided by operating activities increased by $28.3 million, reaching $274.8 million in fiscal year 2025 compared to $246.5 million in 2024[223] - Net cash used by investing activities decreased by $50.6 million, totaling $58.3 million in 2025, primarily due to $43.6 million received from the sale of corporate headquarters[225] - Net cash used by financing activities increased by $24.7 million, amounting to $178.4 million in 2025, driven by higher net paydown of long-term debt[226] - Total debt was reduced by $119.0 million, and 5.0 million shares were repurchased under the share repurchase program[204] Assets and Liabilities - Total assets decreased to $2,177.97 million in 2025 from $2,085.18 million in 2024, while total liabilities also decreased to $1,883.75 million from $1,951.87 million[231] - The company had $875.0 million in outstanding debt as of September 30, 2025, consisting of $600.0 million in 2032 Senior Notes and $275.0 million remaining on term loan B[227] - Contractual obligations totaled $2,204.76 million as of September 30, 2025, with long-term debt obligations including interest amounting to $1,204.52 million[232] Interest Rate and Currency Risk - The weighted average interest rate on borrowings under the ABL facility was 5.7% during fiscal year 2025[227] - A 10% increase or decrease in exchange rates for the U.S. dollar versus foreign currencies would have impacted consolidated net sales by approximately 1.8% in fiscal year 2025[252] - A 1.0 percentage point interest rate increase would negatively impact annual interest expense and cash flows by $0.8 million at September 30, 2025[254] - Less than 20% of consolidated net sales were made in currencies other than the U.S. dollar for fiscal years 2025, 2024, and 2023[251] - The company holds $200 million of SOFR denominated interest hedged under an interest rate swap agreement to mitigate interest rate risk[254] - The company uses foreign exchange forward contracts to mitigate exposure to changes in foreign currency exchange rates[253] Credit Risk Management - Credit risk exposure is primarily related to accounts receivable, with a broad customer base mitigating this risk[256] - The allowance for doubtful accounts is deemed sufficient to cover customer credit risks as of September 30, 2025[256] - Derivative instruments expose the company to credit risk in the event of counterparty default, but current exposure is considered mitigated[257] - The company performs ongoing credit evaluations to manage credit risk associated with trade receivables[256] Operational Expenses - SG&A expenses for Sally increased by $22.3 million, or 2.4%, to $945.9 million, representing 45.2% of net sales[214] - BSG's SG&A expenses decreased by $12.2 million, or 2.7%, to $441.9 million, accounting for 27.5% of net sales[215] Impairment and Other Losses - The company recognized an impairment loss of $4.5 million on certain trade names due to decreased projected revenues from a specific product line in fiscal year 2025[248] Working Capital - Working capital increased by $12.9 million to $725.5 million at September 30, 2025, with a current assets to current liabilities ratio of 2.26 to 1.00[220] - Cash and cash equivalents increased to $85.36 million in 2025 from $32.82 million in 2024[231]

Financial Performance - Net loss for Q3 2025 was $61.5 million, or $1.16 per share, compared to a net loss of $43.9 million, or $0.84 per share, in Q3 2024[9] - Total operating expenses for the three months ended September 30, 2025, were $62.352 million, compared to $46.632 million for the same period in 2024, reflecting a 33.7% increase[33] - The net loss for the nine months ended September 30, 2025, was $173.231 million, compared to $132.102 million for the same period in 2024, indicating a 31.1% increase in losses[33] - Cash and cash equivalents decreased to $72.038 million as of September 30, 2025, down from $168.074 million at the end of 2024[34] - The accumulated deficit increased to $1.501 billion as of September 30, 2025, compared to $1.329 billion at the end of 2024[34] - General and administrative expenses for the nine months ended September 30, 2025, were $40.055 million, down from $46.347 million for the same period in 2024, showing a decrease of 13.9%[33] Research and Development - R&D expenses increased to $50.5 million in Q3 2025 from $31.9 million in Q3 2024, driven by increased clinical activities[10] - KSI-101 showed over 50% of patients achieving a ≥15 letter gain in best corrected visual acuity by week 20 in the Phase 1b APEX study[6] - The Phase 3 PEAK and PINNACLE studies of KSI-101 are enrolling at a faster-than-expected pace, evaluating the top two dose levels of 5 mg and 10 mg[6] - Tarcocimab's Phase 3 GLOW2 diabetic retinopathy study is on track for topline data in Q1 2026[6] - The Phase 3 DAYBREAK study has enrolled approximately 690 subjects, with the last visit for the primary endpoint expected in August 2026[6] - KSI-501 is being developed for high prevalence retinal vascular diseases and has completed enrollment in the DAYBREAK study[21] - Kodiak Sciences is actively enrolling patients in the PEAK and PINNACLE studies, which are designed to cover a wide spectrum of MESI patients[29] - KSI-101 is being evaluated in two Phase 3 studies for Macular Edema Secondary to Inflammation (MESI), with topline data readouts anticipated in 4Q 2026 (PEAK) and 1Q 2027 (PINNACLE)[30] Company Outlook - Kodiak expects continued momentum into 2026 with all three Phase 3 assets on track for topline data readouts and the first planned BLA filing[3] - Kodiak Sciences is focused on developing transformative therapeutics for retinal diseases, targeting a $15 billion anti-VEGF market with two Phase 3 studies for Tarcocimab and KSI-501, expecting topline data in 1Q 2026 and 3Q 2026[30] Technology and Innovation - The company’s ABC® Platform utilizes molecular engineering to develop next-generation retinal medicines[30]

Revenue Performance - SurgePays reported third quarter 2025 revenue of approximately $18.7 million, representing a 292% increase year-over-year and a 62% increase sequentially [2]. - The company reaffirmed its revenue guidance for 2026 at $225 million, supported by continued growth in Lifeline subscribers and expansion of prepaid retail distribution [5]. - Torch Wireless, a key growth driver, achieved revenue of $5.6 million with over 125,000 subscribers during the third quarter [4]. - Revenues for the three months ended September 30, 2025, were $18.68 million, a decrease from $51.28 million in the same period of 2024 [17]. Subscriber Growth - LinkUp Mobile surpassed 95,000 recurring active subscribers by the end of the third quarter, driven by expanded retail distribution and competitive pricing [4]. - The company aims to expand its retail locations operating on the SurgePays platform to 100,000, driven by organic growth and new distribution agreements [10]. - SurgePays has onboarded three MVNO partners to date, with additional partnerships in progress, enhancing its high-margin business model [10]. Financial Performance - SurgePays improved its gross profit loss to $(2.6) million in Q3 2025, compared to $(7.8) million in Q3 2024 [10]. - Selling, General and Administrative (SG&A) expenses decreased to $4.2 million, a 32.5% improvement year-over-year from $6.2 million [10]. - Total costs and expenses for the three months ended September 30, 2025, were $25.63 million, compared to $19.05 million in the same period of 2024, representing a 34.5% increase [17]. - Net loss available to common stockholders for the three months ended September 30, 2025, was $7.49 million, compared to a loss of $14.28 million in the same period of 2024 [17]. - Basic and diluted earnings per share for the three months ended September 30, 2025, were both $(0.38), an improvement from $(0.73) in the same period of 2024 [17]. - The company reported a net loss including non-controlling interest of $22.21 million for the nine months ended September 30, 2025, compared to $25.95 million in the same period of 2024 [19]. Cash Flow and Liquidity - Net cash used in operating activities for the nine months ended September 30, 2025, was $17.73 million, compared to $13.41 million in the same period of 2024 [19]. - Net cash provided by financing activities for the nine months ended September 30, 2025, was $7.47 million, a decrease from $23.03 million in the same period of 2024 [19]. - Cash, cash equivalents, and restricted cash at the end of the period were $2.51 million, down from $13.65 million at the end of the same period in 2024 [19]. Other Financial Metrics - The company recognized stock-based compensation of $526.13 thousand for unvested shares related to parties during the nine months ended September 30, 2025 [19]. - The company had a total other income (expense) - net of $(539.16) thousand for the three months ended September 30, 2025, compared to $1.02 thousand in the same period of 2024 [17]. - Total current liabilities increased to $17.7 million as of September 30, 2025, compared to $6.1 million at the end of 2024 [15].

Exhibit 99.1 A2Z Cust2Mate Solutions Corp. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 (Unaudited) (Expressed in US Dollars) A2Z CUST2MATE SOLUTIONSCORP. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 (Unaudited) (Expressed in US Dollars) INDEX | | Page | | --- | --- | | Condensed Consolidated Interim Statements of Financial Position | 3 | | Condensed Consolidated Interim Statements of ...